Enzymebiosystems (ENZB) 0.4000 $ENZB Penny Stocks

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Enzymebiosystems (ENZB) 0.4000 $ENZB

Penny Stocks Reports for EnzymeBioSystems, Sigma Labs, NanoTech Entertainment, Anavex Life Sciences, BIRCHCLIFF, and Pharmacyte Biotech
PR Newswire - Fri Mar 20, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: EnzymeBioSystems (OTCBB:ENZB), Sigma Labs (OTCMKTS:SGLB), NanoTech Entertainment (OTCMKTS:NTEK), Anavex Life Sciences (OTCMKTS:AVXL), BIRCHCLIFF (OTCMKTS:BIREF), and Pharmacyte Biotech (OTCMKTS MCB).

EnzymeBioSystems: A Promotion Best Left Untouched
Hunter Straus - at Seeking Alpha - Mon Mar 16, 11:09PM CDT


EnzymeBioSystems Cleared for OTCQB Listing
ACCESSWIRE - Mon Mar 16, 12:12PM CDT
LAS VEGAS, NV / ACCESSWIRE / March 16, 2015 / EnzymeBioSystems (OTCQB: ENZB) announced that it received notice of approval from OTC Markets Group, Inc. ("OTC Markets" that its stock will be listed on OTCQB Marketplace, effective March 16, 2015. ENZB submitted all the mandatory documents and has met all requirements for listing on the OTCQB Marketplace.

Market Maker Surveillance Report. NNBR, IDT, CTRV, ENZB, HTBX, ESCRP, Losing Stocks With Lowest Price Friction For Tuesday, March 10th 2015
M2 - Wed Mar 11, 4:18AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4960 companies with "abnormal" market making, 1371 companies with positive Friction Factors and 5291 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. NN Inc (NASDAQ:NNBR), IDT Corp (NYSE:IDT), CARDILLO TRAVEL SYS (NASDAQ:CTRV), EnzymeBioSystems (OTC:ENZB), (NASDAQ:HTBX), (NASDAQ:ESCRP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
HTBX: 6.35 (+0.02), CTRV: 5.60 (+0.15), IDT: 17.35 (+0.08), ESCRP: 3.11 (-0.06), NNBR: 25.82 (+0.61)

EnzymeBioSystems' Amooranin preclinical sample batch to be completed by end of February 2015
M2 - Thu Feb 19, 5:13AM CST
Specialist enzymes company EnzymeBioSystems (OTCBB:ENZB) revealed on Wednesday that its preclinical methyl amooranin batch for the prevention of breast cancer nears completion.

Amooranin Preclinical Sample Batch Nears Completion
ACCESSWIRE - Wed Feb 11, 7:00AM CST
LAS VEGAS, NV / ACCESSWIRE / February 11, 2015 / EnzymeBioSystems (OTC:ENZB) announces that its preclinical methyl amooranin batch nears completion. Amooranin is the Company's lead pharmaceutical product. The Company plans to seek the use of methyl amooranin in the prevention of breast cancer.

Preclinical Xenograft Studies Show Positive Results For Amooranin
PR Newswire - Wed Dec 10, 12:45PM CST
EnzymeBioSystems (OTCBB: ENZB) announces that preclinical xenograft studies with methyl amooranin, its lead pharmaceutical product, show positive results in inhibiting human colon carcinoma.

EnzymeBioSystems Announces an Independent Research Group Reported Breast Cancer Preventive Efficacy for a Novel Synthetic Triterpenoid
PR Newswire - Mon Nov 17, 7:30AM CST
EnzymeBioSystems (OTCBB: ENZB) announces, methyl amooranin, its lead pharmaceutical product, shows promise in preventing breast cancer. Based on preclinical research lead by Dr. Anupam Bishayee, Associate Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Northstate University, Elk Grove, CA, methyl amooranin markedly inhibited breast tumor formation in an animal model of breast cancer that mimics human disease. The results were published by the peer-reviewed journal International Journal of Cancer (September 1, 2013 edition). Two additional published studies from Dr. Bishayee's laboratory also looked at possible mechanisms of action of this promising compound in preventing breast cancer. Dr. Bishayee's research was supported by a grant from National Institutes of Health (NIH)/National Cancer Institute (NCI).

EnzymeBioSystems Announces Progress with an Enzyme Compound
PR Newswire - Tue Sep 23, 1:14PM CDT
EnzymeBioSystems (OTCBB: ENZB) (OTCQB: ENZB), announces they have moved further along with the process of evaluating an enzyme compound which they believe has specific therapeutic value in fighting tumors. In an effort to evaluate this compound, management has had a series of meetings with various contract research organizations to enlist their expertise in performing animal studies. The research will study the use of an antitumor natural product called amooranin. Specifically, the two areas of this study will include: 1) an exam of the in vitro cytotoxicity of amooranin against hepatocellular carcinoma cells, and 2) investigate the dose responsive antitumor actions of amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bybit Expands ByPick Game with Broader Market Reach

Updated Category News Views 108

Bybit Plays the Game of Expansion Step right up to Bybit’s latest offering – ByPick Season 2. Some folks might be scratching their heads about what's shifting in this free-to-play space, but here we are, watching a beast that’s a mix between a carnival game and a hedge fund playpen. No money exchanged, just knowledge on the line. That's right, we're diving into a...

Continue Reading
Cemig and Huawei's Bold Network Leap: Power Up

Updated Category News Views 40

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Continue Reading
OI Investors Crack Down: Class Action Filing Looms

Updated Category News Views 53

O-I Glass Under Fire: The Glass Containers Giant Stumbles If you’ve been watching the ticker for O-I Glass, Inc. (NYSE:OI), you know it’s been a rocky road lately. We’re knee-deep in another saga of corporate promises meeting harsh reality. The novel here isn’t just the $1 trillion industry O-I Glass plays in, but the speed at which its fortunes seem to be...

Continue Reading
DEEPBLUE's Panelized Systems Target Low-Rise Markets

Updated Category News Views 28

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

Continue Reading
TagMaster To Acquire Kapsch's RFID Ops in NA Market

Updated Category News Views 5

A Strategic Move in the Transportation Sector Here's a fresh shake-up for the North American transportation sector: TagMaster, alongside its U.S. subsidiary Sensys Networks, is all set to acquire Kapsch TrafficCom's RFID-focused North American components business. This isn't just a minor shuffle—this deal could ripple through the industry, promising strategic uplifts...

Continue Reading
SDI's Bhatt Celebrates Back-to-Back Chicago Titan Wins

Updated Category News Views 35

Second Year in a Row: A Nod to Visionary Leadership Hot off the press, folks. Hardik Bhatt, steering the ship at SDI Presence, is basking in the glory of a repeat recognition as a Chicago Titan 100 honoree. It's not just a headline; it's a testament to Bhatt's leadership prowess and how he plays the IT consultancy game. This isn't your run-of-the-mill award, but a salute...

Continue Reading
Cuisine.K Brings Korean Seafood to Seattle Spotlight

Updated Category News Views 17

Korean Seafood Makes Waves in Seattle Bring out the chopsticks, ‘cause Korean seafood just took Seattle by storm with the Cuisine.K Korean culinary showcase. Hosted by CJ Foods, alongside the Korea Fisheries Association, this event smacked the local food scene square in the face with the unique flavors and techniques of K-Seafood—from students all the way to seasoned...

Continue Reading
Procon Uses Robotics to Revamp Cruise Terminal 5

Updated Category News Views 15

Building Bigger with Robotics at Port Canaveral Robots on a construction site sounds like sci-fi, right? But it's the reality at Port Canaveral's Cruise Terminal 5, where Procon is rolling out its robotic tech magic. This ain't your everyday wrench-and-spanner job; we're talking remote-controlled bots capturing 360-degree images. “Regular reality capture can help teams...

Continue Reading
AI Use Hits 93% in Health Systems' Digital Shift

Updated Category News Views 26

Healthcare's AI Surge: Jumping the Adoption Hurdle The digital health landscape isn't just humming along—it's hitting high gear. AI, once the shiny toy in innovation's toolkit, is now a fixture in 93.2% of healthcare systems according to CHIME's latest findings. For anyone keeping score, that's a hefty leap and paints a picture where AI isn't just in the game, it's...

Continue Reading
Xavier Ochsner Opens State-of-the-Art Medical School

Updated Category News Views 106

A New Era for Medical Education in New Orleans If you're familiar with New Orleans, you know it's a city defined by its vibrancy, culture, and resilience. Well, the Xavier Ochsner College of Medicine is adding to that narrative with the opening of their spanking new Center for Medical Education. It's a project that promises to shake things up in the best possible way for...

Continue Reading

Top 5 Most Recently Viewed Articles

Ascletis Advances ASC47 with Encouraging Phase Ib Study Results

Updated Category News Views 313

Exciting Developments in ASC47 Research Ascletis Pharma Inc. is making significant strides in the realm of obesity treatment with its promising candidate, ASC47. This innovative drug is designed to be an adipose-targeted, muscle-preserving solution aimed at tackling obesity. Recent Phase Ib studies have provided compelling pharmacokinetic data and weight loss outcomes,...

Continue Reading
USAA Federal Savings Bank Ordered to Improve Safety Practices

Updated Category News Views 279

USAA Federal Savings Bank Faces Regulatory Scrutiny The U.S. Office of the Comptroller of the Currency (OCC) has recently directed USAA Federal Savings Bank to rectify several regulatory deficiencies classified as unsafe. These issues, which the bank has grappled with for a number of years, reflect gaps in management practices, earnings strategies, information technology...

Continue Reading
RoosterBio and Thermo Fisher Team Up for Advanced Cell Therapies

Updated Category News Views 379

RoosterBio and Thermo Fisher: A Game-Changing Collaboration RoosterBio, Inc., a prominent supplier of adult human mesenchymal stem/stromal cells (hMSCs), has announced a strategic collaboration with Thermo Fisher Scientific. This partnership aims to enhance the manufacturing processes for groundbreaking cell and exosome therapies, promising to make significant advances in...

Continue Reading
Nvidia's Datacenter Revenue Anticipations for Q4 Set to Surge

Updated Category News Views 136

Nvidia's Positive Outlook for Datacenter Revenues in Q4 Analysts from Bernstein are feeling optimistic about Nvidia’s (NASDAQ: NVDA) datacenter revenues as the fourth quarter approaches. Their analysis indicates that we can anticipate a significant rise in revenue, driven by recent advancements in Nvidia's product lineup. Insights from Recent Discussions After a...

Continue Reading
Impact of Financial Status on Longevity Among Older Adults

Updated Category News Views 194

Understanding Longevity Disparities Among Older Adults A recent analysis has revealed a stark reality concerning older adults and their financial stability. Research indicates that those earning $20,000 or less annually tend to die on average nine years earlier than individuals earning $120,000 or more. This significant disparity highlights the urgent need to address the...

Continue Reading